SCP
FOLD

Sender Company & Partners’s Amicus Therapeutics FOLD Stock Holding History

Sender Company & Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-34,540
Closed -$272K – 230
2025
Q3 		$272K Buy
+34,540
New +$246K 0.03% 354

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sender Company & Partners's FOLD Position: Q4 2025 in Review

Sender Company & Partners sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 34,540 shares — an estimated $272K sold.

Sender Company & Partners first reported a position in FOLD in Q3 2025 and held it in 1 quarter. The position peaked at $272K in Q3 2025. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Sender Company & Partners reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sender Company & Partners sold 34,540 Amicus Therapeutics shares in Q4 2025, an estimated $272K.
  • Sender Company & Partners first reported a position in Amicus Therapeutics in Q3 2025 and held it in 1 quarter.
  • Sender Company & Partners's Amicus Therapeutics position peaked at $272K in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Sender Company & Partners's 13F filing for Q4 2025, filed 17 Feb 2026.